We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Heritage Mining Ltd | CSE:HML | CSE | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.005 | 9.09% | 0.06 | 0.06 | 0.07 | 0.06 | 0.055 | 0.055 | 480,000 | 20:12:56 |
RNS Number:6443P Henderson Morley PLC 11 September 2003 FOR IMMEDIATE RELEASE 11 SEPTEMBER 2003 HENDERSON MORLEY PLC (AIM) Business: Drug Discovery Company ICVT - NEW PHASE II STUDY STARTS IN DERMAL APPLICATION The Directors of Henderson Morley are pleased to announce that the Phase ll study to examine the use of Ionic Contra Viral Therapy ("ICVT") against genital warts in men has now received Ethics Committee approval and may now commence. The study is under the supervision of Dr Humphrey Birley, a consultant in genitourinary medicine, practicing at the Department of Genitourinary medicine at the Cardiff Royal Infirmary in Cardiff. Dr Birley's study will be examining the safety and efficacy of ICVT in the treatment of genital warts in men. Dr. Birley is co-author of the National Guidelines for the treatment of genital warts and has had numerous papers published on the subject. Preliminary results are expected during the first half of 2004. The data created by this study will be used to attract further commercial partners for the ICVT platform. This open label**, dose-escalating*** Phase ll study is directed against genital warts in men that have proven resistant to other forms of treatment, which is caused by the Human Papilloma Virus. The Company believes success in this study should have important implications for the treatment of these other conditions. ENDS Copies of this announcement will be available free of charge to the public at the Company's registered office at Metropolitan House, 2 Salisbury Road, Moseley, Birmingham, B13 8JS and at the offices of Brewin Dolphin Securities Ltd, 34 Lisbon Street, Leeds LS1 4LX for 14 days. Enquiries: HENDERSON MORLEY PLC Tel: 0121 442 4600 Andrew Knight, Chairman BREWIN DOLPHIN SECURITIES LTD Tel: 0113 241 0126 Neil Baldwin BARNES AND WALTERS LTD Tel: 020 7430 1600 Maxine Barnes Mobile 07860 489571 Notes to Editors: ** Open label studies are when the patient and the doctor treating them are both aware of the drugs being used in the study. *** Dose escalating studies are when the dose of the drug being used to treat the patient is gradually increased from very low doses to higher doses, depending on the clinical response. About Human Papilloma Virus (HPV) infections HPV is the name given to a group of more than 80 different strains of virus associated with a variety of epidermal warts and skin lesions, some of which are associated with cancer. Low risk sub types (type 6 and 11) are associated with genital warts, but high risk subtypes (type 16 and 18) cause cancer of the cervix and anus, and also cause dysplasias of anogenital tissues. About Genital warts Genital warts (a form of HPV infection) is one of the most common sexually transmitted diseases in the world. The Centers for Disease Control and Prevention (CDC) estimates close to 5.5 million new genital HPV cases occur each year in the USA (approximately 2% of the population), which is approximately one third of all sexually transmitted diseases. It is estimated that 24 million people in the US are infected with HPV at any given time (approximately 10% of the population). Again, in the US, nearly three out of four Americans between the ages of 15 and 49 have been infected with genital HPV) in their lifetimes. Approximately two thirds of people who have sexual contact with genital warts will develop warts within 3 months of contact. (NIAID figures). Figures for the incidence in South East Asia and other markets are more difficult to determine, however the incidence in many developing countries far exceed that of more developed nations. The most commonly used treatments are essentially ablative, causing the destruction of the infected tissues either chemically or physically. This often causes a severe local inflammatory response which may be both painful and cosmetically unacceptable. This information is provided by RNS The company news service from the London Stock Exchange END RESKFLBFXKBZBBL
1 Year Heritage Mining Chart |
1 Month Heritage Mining Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions